SCHEMBL9164081

SCHEMBL9164081

C1=Cc2ccccc2NC(OCc2ccccc2)=C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
TNKS2 Q9H2K2 2/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A3 Q01959 2/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
PTGS1 P23219 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTGS2 P35354 1/20 0.35
HIF1A Q16665 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAOA P21397 8/20 0.35
MAOB P27338 8/20 0.35
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193087 0.79 ALOX15 (0.42) MAPTGAAL3MBTL1TDP1RAB9A
SCHEMBL10880606 0.77 GAA (0.40) MAPTGAATSHRMAPK1
SCHEMBL6098708 0.75 MAPT (0.48) MAPTGAALMNAL3MBTL1MAPK1
Hydrochloric Acid SCHEMBL28604267 0.74 GAA (0.44) MAPTGAAMAOAMAOBTSHR
SCHEMBL10345713 0.69 MAPT (0.41) MAPTGAALMNACYP1A2CYP2C19
SCHEMBL28658376 0.69 MAPT (0.41) MAPTGAALMNATSHRMAPK1
SCHEMBL27552412 0.68 MAPT (0.40) MAPTGAARAB9ASMN1; SMN2
SCHEMBL28592964 0.66 MAPT (0.35) MAPTGAARAB9ASMN1; SMN2
SCHEMBL3732226 0.66 GAA (0.50) MAPTGAALMNASMN1; SMN2
SCHEMBL7414784 0.65 MAPT (0.54) MAPTGAARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970125-B1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-07-18 EP disclosed
US-9956213-B2 Substituted naphthyridine and quinoline compounds as MAO inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2018-05-01 US disclosed
US-20170312263-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE LLC 2017-11-02 US disclosed
US-20170273968-A1 MAO-B INHIBITORS AND REHABILITATION DART NEUROSCIENCE, LLC 2017-09-28 US disclosed
CN-107073296-A MAO B inhibitor and rehabilitation 达特神经科学(开曼)有限公司 2017-08-18 CN disclosed
EP-3194026-A1 MAO-B INHIBITORS AND REHABILITATION Dart NeuroScience (Cayman) Ltd. (KY) 2017-07-26 EP disclosed
US-9675605-B2 Substituted naphthyridine and quinoline compounds as MAO inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-06-13 US disclosed
WO-2016044635-A1 MAO-B INHIBITORS AND REHABILITATION DART NEUROSCIENCE, LLC (US) 2016-03-24 WO disclosed
US-20160074377-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE, LLC 2016-03-17 US disclosed
EP-2970125-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2016-01-20 EP disclosed
US-9150572-B2 Substituted naphthyridine and quinoline compounds as MAO inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-10-06 US disclosed
US-9102674-B2 Substituted naphthyridine and quinoline compounds as MAO inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-08-11 US disclosed
US-20140315944-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE LLC 2014-10-23 US disclosed
WO-2014158916-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE, LLC (US) 2014-10-02 WO disclosed
US-20140275548-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS DART NEUROSCIENCE LLC 2014-09-18 US disclosed
EP-0380355-B1 Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs SMITHKLINE BEECHAM CORP (US) 1995-01-11 EP disclosed
EP-0380355-A2 Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-08-01 EP disclosed
US-4861771-A Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs SMITHKLINE BECKMAN CORPORATION (US) 1989-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160074377-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS MAOB, MAOA, PNMT MAPT 873/4885GAA 57/4885TNKS2 1828/4885
US-20170312263-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS MAOB, MAOA, PNMT MAPT 888/4885GAA 59/4885TNKS2 1918/4885
US-20140275548-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS MAOB, MAOA, PNMT MAPT 873/4885GAA 57/4885TNKS2 1828/4885
US-20140315944-A1 SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS MAOB, MAOA, PNMT MAPT 888/4885GAA 59/4885TNKS2 1918/4885
US-20170273968-A1 MAO-B INHIBITORS AND REHABILITATION MAOB, MAOA, HTR2B MAPT 807/4885GAA 157/4885TNKS2 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.